Impact of overexpression of Sushi repeat-containing protein X-linked 2 gene on outcomes of gastric cancer

Journal of Surgical Oncology

Volumn 109, Issue 8, 2014, Pages 836-840

  Yamada, Takanobu ^a,b   Oshima, Takashi ^a,b   Yoshihara, Kazue ^a   Sato, Tsutomu ^c   Nozaki, Akito ^a   Shiozawa, Manabu ^c   Ota, Mitsuyoshi ^a   Yoshikawa, Takaki ^c   Akaike, Makoto ^c   Numata, Kazushi ^a   Rino, Yasushi ^b   Kunisaki, Chikara ^a   Tanaka, Katsuaki ^a   Imada, Toshio ^b   Masuda, Munetaka ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

Author keywords

gastric cancer; prognosis; SRPX2

Indexed keywords

CELL ANTIGEN; COMPLEMENTARY DNA; MESSENGER RNA;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; DNA SYNTHESIS; FEMALE; GASTRIC CANCER CELL LINE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; STOMACH CANCER; SUSHI REPEAT CONTAINING PROTEIN X LINKED 2 GENE; TUMOR GENE; TUMOR INVASION;

GASTRIC CANCER; PROGNOSIS; SRPX2;

AGED; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM STAGING; NERVE TISSUE PROTEINS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84900555083     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23602     Document Type: Article

References (21)

1. World Health Organization. Fact sheet no. 297, Cancer. http://www.who.int/mediacentre/factsheets/fs297/en/index.html. Published 2012.
2. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
3. Bang YJ, Kim YW, Yang HK, et al.: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-321.
4. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
5. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
6. Koizumi W, Narahara H, Hara T, et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008; 9: 215-221.
7. Cunningham D, Starling N, Rao S, et al.: Upper gastrointestinal clinical studies group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
8. Ajani JA, Rodriguez W, Bodoky G, et al.: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J Clin Oncol 2010; 28: 1547-1553.
9. Ohtsu A, Shah MA, Van Cutsem E, et al.: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976.
10. Bang YJ, Van Cutsem E, Feyereislova A, et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
11. Kurosawa H, Goi K, Inukai T, et al.: Two candidate downstream target genes for E2A-HLF. Blood 1999; 93: 321-332.
12. Tanaka K, Arao T, Maegawa M, et al.: SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. Int J Cancer 2009; 124: 1072-1080.
13. Sato T, Oshima T, Yamamoto N, et al.: Clinical significance of SPARC gene expression in patients with gastric cancer. J Surg Oncol 2013; 108: 364-368.
14. Tanaka K, Arao T, Tamura D, et al.: SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer. PLoS ONE 2012; 7: e27922. doi: 10.1371/journal.pone.0027922. Epub2012 Jan 5.
15. Øster B, Linnet L, Christensen LL, et al.: Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer. Int J Cancer 2013; 132: 2303-2315.
16. O'Leary JM, Bromek K, Black GM, et al.: Backbone dynamics of complement control protein (CCP) modules reveals mobility in binding surfaces. Protein Sci 2004; 13: 1238-1250.
17. Callebaut I, Gilgès D, Vigon I, et al.: HYR, an extracellular module involved in cellular adhesion and related to the immunoglobulin-like fold. Protein Sci 2000; 9: 1382-1390.
18. Royer-Zemmour B, Ponsole-Lenfant M, Gara H, et al.: Epileptic and developmental disorders of the speech cortex: Ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR. Hum Mol Genet 2008; 17: 3617-3630.
19. Royer B, Soares DC, Barlow PN, et al.: Molecular evolution of the human SRPX2 gene that causes brain disorders of the Rolandic and Sylvian speech areas. BMC Genet 2007; 8: 72.
20. Dallas MR, Chen SH, Streppel MM, et al.: Sialofucosylated podocalyxin is a functional E- and L-selectin ligand expressed by metastatic pancreatic cancer cells. Am J Physiol Cell Physiol 2012; 303: C616-C624.
21. Borsig L, Wong R, Hynes RO, et al.: Synergistic effects of L-,P-selectin in facilitating tumor metastasis can involve non-mucin ligands, implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA 2002; 99: 2193-2198.